Navarixin

DRUG4 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

AsthmaCOPDCastration Resistant Prostate CancerMicrosatellite Stable Colorectal CancerNeutrophilic AsthmaNon-small Cell Lung CancerSolid Tumors

Phase 2

Neutrophilic Asthma Study With Navarixin (MK-7123, SCH 527123) (MK-7123-017)(COMPLETED)

CompletedNCT00632502

Merck Sharp & Dohme LLCNeutrophilic Asthma

Start: 2008-05-01End: 2009-02-01Updated: 2019-01-02

Efficacy and Safety of Navarixin (SCH 527123) in Participants With Allergen-Induced Asthma (P05363)

CompletedNCT00688467

Merck Sharp & Dohme LLCAsthma

Start: 2008-06-01End: 2009-03-01Updated: 2019-01-02

Long-Term Study of the Effects of Navarixin (SCH 527123, MK-7123) in Participants With Moderate to Severe COPD (MK-7123-019)

TerminatedNCT01006616

Merck Sharp & Dohme LLCCOPD

Start: 2009-10-01End: 2011-11-01Updated: 2019-01-02

Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)

CompletedNCT03473925

Merck Sharp & Dohme LLCCastration Resistant Prostate Cancer, Microsatellite Stable Colorectal Cancer, Non-small Cell Lung Cancer +1

Start: 2018-04-10End: 2021-05-19Updated: 2024-08-28

Related Papers

CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial.

2024-02-0738 citations

A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer.

2022-03-1522 citations